About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3693373
Allelic
Composition
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(Tal1-tTA)19Dgt/0
Genetic
Background
involves: C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Tal1-tTA)19Dgt mutation (2 available)
Tg(tetO-BCR/ABL1)2Dgt mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

hematopoietic system
• 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells and a 26-fold increase after 21 days; at both points, granulocyte-macrophage progenitor (GMP) percentage is increased 3-fold, while megakaryocyte-erythroid progenitors (MEP) show a 3-fold decrease
• common myeloid precursors (CMP) show a 2-fold decrease and a 1.5-fold increase at 12 and 21 days, respectively
• some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages
• bone marrow of diseased mice is hypercellular
• increased numbers of cells of lymphoid and myeloid lineage are detected in diseased mice
• increased numbers of megakaryocytes are detected in bone marrow and spleen of diseased mice
• bone marrow contains increased ratio of myeloid and erythroid cells dominated by granulocytic forms
• increase in immature myeloid cells is observed
• absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)
• readministration of tet results in reversion of leukocytosis in approximately ~4 days
• percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice
• readministration of tet results in reversion of neutrophilia in approximately ~4 days
• 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells
• after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points
• after induction by withdrawal of tet treatment, splenomegaly invariably results
• readministration of tet results in disappearance of palpable splenomegaly
• induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen

immune system
• some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages
• absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)
• readministration of tet results in reversion of leukocytosis in approximately ~4 days
• percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice
• readministration of tet results in reversion of neutrophilia in approximately ~4 days
• after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points
• after induction by withdrawal of tet treatment, splenomegaly invariably results
• readministration of tet results in disappearance of palpable splenomegaly
• induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen
• infiltration by myeloid cells is observed

liver/biliary system
• infiltration of liver by myeloid cells is observed after induction; 57% of mice display hepatomegaly

respiratory system
• infiltration by myeloid cells is observed, occasionally resulting in focal pulmonary hemorrhages

digestive/alimentary system
• infiltration of lamina propria by myeloid cells is observed

neoplasm
• some mice develop lymphomas
• readministration of tet results in disappearance of lymphomas (except in 1 case)
• 2 animals with fulminant disease displayed skin chloromas (granulocytic sarcomas)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
chronic myeloid leukemia DOID:8552 OMIM:608232
J:96511


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/14/2017
MGI 6.11
The Jackson Laboratory